Fate Therapeutics downgraded to neutral from outperform at Wedbush

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Fate Therapeutics Inc.

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply